Open filling lines fail inspections when bioburden assumptions go unproven. See the five aseptic processing gaps FDA and Annex 1 inspectors cite.

GMP risk remediation improves pharmaceutical quality by fixing the systemic causes of compliance gaps at the source, so risk falls and problems stop recurring. Here is how it works.

The same sentence appears in most sterile FDA warning letter findings. Learn what inspectors mean by it and how to close the gap before your audit.